Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
November 02 2023 - 8:30AM
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage
pharmaceutical company focused on modulating lipid-signaling
pathways to develop treatments for people living with cancer, pain,
and neurological conditions, today announced that the research
group working with Steven Laviolette, Ph.D., Scientific Advisor at
Artelo Biosciences and Professor in the Schulich School of Medicine
at the University of Western Ontario, Canada, will be presenting at
Neuroscience 2023. The conference will be hosted by the Society for
Neuroscience and held November 11-15, 2023 at the Walter E.
Washington Convention Center in Washington, D.C. Neuroscience 2023
is the world’s largest source of emerging news on brain science and
health, with 25,000 neuroscience researchers and clinicians
expected in attendance.
One poster presentation will discuss Artelo’s Fatty Acid Binding
Protein 5 (FABP5) inhibitor, ART26.12, and will provide an overview
of ART26.12’s ability to modulate key signaling pathways that
control depressive and anxiety-related behaviors. Another poster
will present work on Artelo’s proprietary cocrystal of cannabidiol
and tetramethylpyrazine, ART12.11, which has demonstrated improved
efficacy and bioavailability compared to cannabidiol alone in a
model of anxiety and depression.
“We are very pleased to have two of our programs being featured
at this year’s conference,” commented Dr. Andrew Yates, Chief
Scientific Officer at Artelo Biosciences. “This exciting science
presented in both anxiety and depression further validates two
portfolio assets as potential opportunities in the neuroscience
space, as Artelo advances as a clinical-stage pharmaceutical
company.”
Artelo plans to file an IND (Investigational New Drug)
application with the Food and Drug Administration (FDA) in the
first half of 2024 to develop ART26.12 for the treatment of
neuropathic pain, which follows our previously announced FDA
Pre-IND meeting earlier this year. ART26.12 has demonstrated a
positive effect in numerous animal models of painful neuropathies,
including chemotherapy-induced peripheral neuropathy (CIPN) and
diabetic neuropathy.
For more information about the conference, please visit
Neuroscience 2023.
About ART26.12Fatty Acid Binding Proteins
(FABPs) are a family of intracellular proteins that chaperone
lipids including endocannabinoids and fatty acids. Various
inhibitors of FABPs may be particularly useful for the treatment of
specific cancers, neuropathic and nociceptive pain, and anxiety
disorders. ART26.12, Artelo’s lead FABP inhibitor compound, is a
selective inhibitor of FABP5. While developing our lead molecule
for chemotherapy-induced peripheral neuropathy, additional
compounds from our extensive library of potent and selective
inhibitors of FABPs have been identified and selected for
advancement towards regulatory-enabling studies in cancer and other
areas of high-unmet need where inhibition of FABPs show significant
promise.
About ART12.11ART12.11 is a proprietary
cocrystal composition of cannabidiol (CBD). It is isolated as a
single crystalline form that offers biopharmaceutic advantages over
compositions of CBD that exhibit solid polymorphism (i.e., the
ability to manifest different forms). Preclinical studies of
ART12.11 have exhibited superior pharmacokinetics and improved
efficacy compared to other forms of CBD. With superior
pharmaceutical properties and preclinical results, Artelo believes
a more consistent and improved bioavailability profile may
ultimately lead to improved safety and efficacy in humans, thus
making ART12.11 a preferred CBD pharmaceutical composition.
About Painful NeuropathiesPeripheral neuropathy
refers to a condition in which there is damage to the peripheral
nerves. These nerves are responsible for transmitting signals
between the central nervous system and the rest of the
body. CIPN is a common and often painfully debilitating
complication of cancer therapies, sometimes resulting in reduction
or cessation of treatment. No currently approved treatment exists
for CIPN. Diabetic neuropathy refers to a type of nerve damage that
occurs as a complication of diabetes. It is caused by long-term
high blood sugar levels, which can lead to damage of the blood
vessels and nerves throughout the body. The prevalence of diabetic
neuropathy is significant due to the increasing number of people
with diabetes worldwide.
About Artelo BiosciencesArtelo Biosciences,
Inc. is a clinical stage pharmaceutical company dedicated to
the development and commercialization of proprietary therapeutics
that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, neuropathy, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking StatementsThis press release
contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and Private Securities Litigation
Reform Act, as amended, including those relating to the Company’s
product development, clinical and regulatory timelines, market
opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth
opportunities and other statement that are predictive in nature.
These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s filings with the
Securities and Exchange Commission, including our ability to raise
additional capital in the future. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise, except to the extent required by
applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Aug 2023 to Aug 2024